PRECISION BIOSCIENCES, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 109
- Market Cap
- -
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients with Chronic Hepatitis B
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06680232
- Locations
- 🇭🇰
Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Hong Kong
🇲🇩ICS ARENSIA Exploratory Medicine SRL, Chisinau, Moldova, Republic of
🇳🇿New Zealand Clinical Research, Auckland, New Zealand
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
- Conditions
- Hematologic MalignancyCD19 Expressing Malignancies
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04649112
- Locations
- 🇺🇸
Banner MDA, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04171843
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
- Conditions
- Non-Hodgkin's Lymphoma, RelapsedChronic Lymphoid Leukemia in RelapseNon-Hodgkin's Lymphoma RefractoryChronic Lymphocytic LeukemiaLymphoma, Non-HodgkinLeukemia, Lymphocytic, ChronicB-cell Chronic Lymphocytic LeukemiaB-cell Non Hodgkin LymphomaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04030195
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Columbia University, New York, New York, United States